PDEX Stock Overview
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$15.95|
|52 Week High||US$32.00|
|52 Week Low||US$12.40|
|1 Month Change||-0.25%|
|3 Month Change||-1.54%|
|1 Year Change||-49.04%|
|3 Year Change||19.93%|
|5 Year Change||153.17%|
|Change since IPO||193.33%|
Recent News & Updates
Is Now The Time To Look At Buying Pro-Dex, Inc. (NASDAQ:PDEX)?
Pro-Dex, Inc. ( NASDAQ:PDEX ), is not the largest company out there, but it received a lot of attention from a...
Is Pro-Dex (NASDAQ:PDEX) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|PDEX||US Medical Equipment||US Market|
Return vs Industry: PDEX underperformed the US Medical Equipment industry which returned -24.5% over the past year.
Return vs Market: PDEX underperformed the US Market which returned -20.8% over the past year.
|PDEX Average Weekly Movement||9.9%|
|Medical Equipment Industry Average Movement||10.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: PDEX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: PDEX's weekly volatility (10%) has been stable over the past year.
About the Company
|1978||118||Rick Van Kirk||https://www.pro-dex.com|
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries.
Pro-Dex Fundamentals Summary
|PDEX fundamental statistics|
Is PDEX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PDEX income statement (TTM)|
|Cost of Revenue||US$26.05m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.51|
|Net Profit Margin||4.79%|
How did PDEX perform over the long term?See historical performance and comparison
Is PDEX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 6/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PDEX?
Other financial metrics that can be useful for relative valuation.
|What is PDEX's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does PDEX's PE Ratio compare to its peers?
|PDEX PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
TRIB Trinity Biotech
Price-To-Earnings vs Peers: PDEX is good value based on its Price-To-Earnings Ratio (31x) compared to the peer average (53.6x).
Price to Earnings Ratio vs Industry
How does PDEX's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Earnings vs Industry: PDEX is good value based on its Price-To-Earnings Ratio (31x) compared to the US Medical Equipment industry average (33.6x)
Price to Earnings Ratio vs Fair Ratio
What is PDEX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||31x|
|Fair PE Ratio||75.9x|
Price-To-Earnings vs Fair Ratio: PDEX is good value based on its Price-To-Earnings Ratio (31x) compared to the estimated Fair Price-To-Earnings Ratio (75.9x).
Share Price vs Fair Value
What is the Fair Price of PDEX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PDEX ($15.95) is trading below our estimate of fair value ($22.14)
Significantly Below Fair Value: PDEX is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: PDEX is good value based on its PEG Ratio (0.4x)
Discover undervalued companies
How is Pro-Dex forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PDEX's forecast earnings growth (72.3% per year) is above the savings rate (1.9%).
Earnings vs Market: PDEX's earnings (72.3% per year) are forecast to grow faster than the US market (13.7% per year).
High Growth Earnings: PDEX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PDEX's revenue (2.8% per year) is forecast to grow slower than the US market (8.3% per year).
High Growth Revenue: PDEX's revenue (2.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PDEX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Pro-Dex performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PDEX has a large one-off loss of $1.4M impacting its March 31 2022 financial results.
Growing Profit Margin: PDEX's current net profit margins (4.8%) are lower than last year (19.1%).
Past Earnings Growth Analysis
Earnings Trend: PDEX's earnings have grown by 6.9% per year over the past 5 years.
Accelerating Growth: PDEX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PDEX had negative earnings growth (-75.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (12.9%).
Return on Equity
High ROE: PDEX's Return on Equity (8.4%) is considered low.
Discover strong past performing companies
How is Pro-Dex's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: PDEX's short term assets ($28.1M) exceed its short term liabilities ($7.7M).
Long Term Liabilities: PDEX's short term assets ($28.1M) exceed its long term liabilities ($13.9M).
Debt to Equity History and Analysis
Debt Level: PDEX's net debt to equity ratio (28.4%) is considered satisfactory.
Reducing Debt: PDEX's debt to equity ratio has increased from 0.8% to 54.9% over the past 5 years.
Debt Coverage: PDEX's debt is well covered by operating cash flow (42.2%).
Interest Coverage: PDEX's interest payments on its debt are well covered by EBIT (11.5x coverage).
Discover healthy companies
What is Pro-Dex current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PDEX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PDEX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PDEX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PDEX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PDEX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rick Van Kirk (60 yo)
Mr. Richard Lee Van Kirk, Jr., also known as Rick, has been the Chief Executive Officer, President and Director of Pro-Dex Inc., since January 12, 2015 and has been its Chief Operating Officer since April...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD1.98M) is above average for companies of similar size in the US market ($USD760.83K).
Compensation vs Earnings: Rick's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: PDEX's management team is seasoned and experienced (7.4 years average tenure).
Experienced Board: PDEX's board of directors are considered experienced (9.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PDEX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pro-Dex, Inc.'s employee growth, exchange listings and data sources
- Name: Pro-Dex, Inc.
- Ticker: PDEX
- Exchange: NasdaqCM
- Founded: 1978
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$57.718m
- Shares outstanding: 3.62m
- Website: https://www.pro-dex.com
Number of Employees
- Pro-Dex, Inc.
- 2361 McGaw Avenue
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/30 00:00|
|End of Day Share Price||2022/06/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.